Friday, February 23, 2024
CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, have recently announced a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services. CATUG is known for its expertise in integrated nucleic acid and drug delivery CRDMO services, while Crystal Bio specializes in analytical services for biologics in CMC, preclinical development, and clinical stages. Together, these companies aim to offer comprehensive nucleic acid services and analytical solutions in the North American market.
The collaboration has led to the creation of the CATUG-Crystal Joint Lab, which will address analytical challenges in the mRNA and nucleic acid therapeutics field. The lab will provide advanced characterization capabilities and a wide range of analytical services to support various stages of drug development. Joint lab locations in New Jersey and Boston ensure accessibility, quality, speed, and flexibility in service delivery.
Crystal Pharmatech, highlighted the increasing demand for analytical solutions in mRNA and nucleic acid therapeutics. Dr. Chen expressed excitement about the partnership with CATUG, emphasizing their commitment to providing top-notch analytical services to support nucleic acid discovery and development in North American pharmaceutical hubs.
CATUG, also expressed enthusiasm for the partnership with Crystal Bio. She recognized Crystal Bio's expertise in handling analytical challenges across various biologic products and emphasized their shared vision for innovation, quality, and excellence. Dr. Jin noted that the launch of the CATUG-Crystal joint lab demonstrates their commitment to delivering advanced services crucial for different stages of drug development.
CATUG and Crystal Bio are confident that their collaboration will deliver best-in-class analytical services and drive advancements in nucleic acid-based drug development within the North American market.
Source: prnewswire.com
